Date:8/6/2009

--- ---- ---- (Unaudited) (Unaudited) ----------- ----------- Revenue $3,781 $3,863 $7,576 $7,592 Operating expenses: Research and development 7,096 8,356 14,385 16,049 General and administrative 1,453 2,289 3,383 4,729 ----- ----- ----- ----- Total operating expenses 8,549 10,645 17,768 20,778 ----- ------ ------ ------ Loss from operations (4,768) (6,782) (10,192) (13,186) Interest income 8 156 35 417 Interest expense, net (52) 73 (65) (48) Other 3 3 (268) 7 ---- ---- ---- ---- Net loss $(4,809) $(6,550) $(10,490) $(12,810) ======= ======= ======== ======== Basic and diluted loss per share $(0.05) $(0.08) $(0.12) $(0.17) ====== ====== ====== ====== Shares used in computing basic and diluted net loss per share 92,053 78,707 90,356 77,073 ====== ====== ====== ====== GenVec, Inc. Selected Balance Sheet Information (in thousands) June 30, December 31, 2009 2008 ---- ---- (Unaudited) Cash and investments $12,628 $17,357 Working capit
'/>"/>

SOURCE GenVec, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. GenVec Expands Contract Supporting Malaria Vaccine Program
2. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
3. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. OncoGenex Reports Second Quarter 2009 Financial Results
6. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
7. PDI Reports 2009 Second Quarter Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. NxStage Reports Second Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia